Sexual function after breast cancer.

INTRODUCTION Breast cancer (BC) remains the most common non-skin cancer in women and an increasing number are living as BC survivors. AIM The aim of this article is to evaluate the impact of the first diagnosis of invasive BC and its treatment, menopausal symptoms, and body image on sexual function. METHODS The BUPA Foundation Health and Wellbeing after Breast Cancer Study is a prospective cohort study of 1,684 women recruited within 12 months of their first diagnosis with invasive BC. Each participant completed an enrollment questionnaire (EQ) and first follow-up questionnaire (FQ1) 12 months post-EQ. MAIN OUTCOME MEASURE Sexual function was evaluated by the Menopause-Specific Quality of Life Questionnaire embedded within the FQ1. RESULTS Of the 1,011 women in the analyses, 70% experienced sexual function problems and 77% reported vasomotor symptoms. Women experiencing sexual function problems were postmenopausal (P = 0.02), experienced vasomotor symptoms (P < 0.01), and used aromatase inhibitors (P = 0.03). Women with vasomotor symptoms were twice as likely to experience sexual function problems (odds ratio [OR] 1.93, 95% confidence interval [CI] 141, 2.63; P < 0.001). This association was more extreme for women on aromatase inhibitors (OR 3.49, 95% CI 1.72, 7.09; P = 0.001) but did not persist in women not using endocrine therapies (OR 1.41, 95% CI 0.84, 2.36; P = 0.19). Women on aromatase inhibitors were more likely to report sexual function problems (OR 1.50, 95% CI 1.0, 2.2, P = 0.04) and women with body image issues were 2.5 times more likely to report sexual function problems (OR 2.5 95% CI 1.6, 3.7, P < 0.001). Women using tamoxifen were not more likely to experience sexual function problems (OR 1.1, 95% CI 0.8, 1.5, P = 0.6); however, women with body image issues were twice as likely to experience sexual function problems (OR 2.1, 95% CI 1.5, 3.0, P < 0.001). CONCLUSION Seventy percent of partnered BC survivors less than 70 experienced sexual function problems. Sexual problems are related to the use of aromatase inhibitors which can exacerbate menopausal symptoms.

[1]  P. Sismondi,et al.  Effects of surgical and adjuvant therapies for breast cancer on sexuality, cognitive functions, and body weight. , 2010, The journal of sexual medicine.

[2]  S. Davis,et al.  Psychological well-being in a cohort of women with invasive breast cancer nearly 2 years after diagnosis , 2010, Supportive Care in Cancer.

[3]  R. Wolfe,et al.  Lack of knowledge of hormone receptor status and use of endocrine therapy in invasive breast cancer. , 2009, Journal of women's health.

[4]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[5]  P. Ganz,et al.  Addressing intimacy and partner communication after breast cancer: a randomized controlled group intervention , 2009, Breast Cancer Research and Treatment.

[6]  O. Harmancioğlu,et al.  Psychosexual and Body Image Aspects of Quality of Life in Turkish Breast Cancer Patients: A Comparison of Breast Conserving Treatment and Mastectomy , 2009, Tumori.

[7]  M. Friedlander,et al.  The impact of aromatase inhibitors on sexual functioning: current knowledge and future research directions. , 2008, Breast.

[8]  E. Wight,et al.  Sexual dysfunction after premenopausal stage I and II breast cancer: do androgens play a role? , 2008, Journal of Sexual Medicine.

[9]  L. Schover.  Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Guyatt,et al.  A menopause-specific quality of life questionnaire: development and psychometric properties. , 1996, Maturitas.

[11]  Rory Wolfe,et al.  Use of a cancer registry is preferable to a direct-to-community approach for recruitment to a cohort study of wellbeing in women newly diagnosed with invasive breast cancer , 2008, BMC Cancer.

[12]  F. Holmes,et al.  Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. LaCroix,et al.  Night sweats, sleep disturbance, and depression associated with diminished libido in late menopausal transition and early postmenopause: baseline data from the Herbal Alternatives for Menopause Trial (HALT). , 2007, American journal of obstetrics and gynecology.

[14]  D. Cameron,et al.  Quality of life and sexual function after high-dose or conventional chemotherapy for high-risk breast cancer , 2006, British Journal of Cancer.

[15]  E. Laan,et al.  Female sexual satisfaction and pharmaceutical intervention: a critical review of the drug intervention studies in female sexual dysfunction. , 2006, The journal of sexual medicine.

[16]  J. Cuzick,et al.  Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer , 2006, Breast Cancer Research and Treatment.

[17]  M. Krychman.  Sexual rehabilitation medicine in a female oncology setting. , 2006, Gynecologic oncology.

[18]  N. Watts,et al.  Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. , 2006, Archives of internal medicine.

[19]  Patricia A. Ganz,et al.  Breast cancer survivors: Psychosocial concerns and quality of life , 2005, Breast Cancer Research and Treatment.

[20]  P. Ganz,et al.  Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. , 2004, Journal of the National Cancer Institute.

[21]  A. V. D. Van Der Zee,et al.  Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy , 2002, British Journal of Cancer.

[22]  P. Ganz,et al.  Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. , 2002, Journal of the National Cancer Institute.

[23]  P. Ganz,et al.  Role of breast reconstructive surgery in physical and emotional outcomes among breast cancer survivors. , 2000, Journal of the National Cancer Institute.

[24]  P. Ganz,et al.  Life after breast cancer: understanding women's health-related quality of life and sexual functioning. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S. Young-McCaughan.  Sexual functioning in women with breast cancer after treatment with adjuvant therapy. , 1996, Cancer nursing.

[26]  G. Guyatt,et al.  A menopause-specific quality of life questionnaire: development and psychometric properties. , 1996, Maturitas.

[27]  S. Grundfest-Broniatowski,et al.  Partial mastectomy and breast reconstruction. A comparison of their effects on psychosocial adjustment, body image, and sexuality , 1995, Cancer.

[28]  P. Ganz,et al.  Breast conservation versus mastectomy. Is there a difference in psychological adjustment or quality of life in the year after surgery? , 1992, Cancer.

[29]  B. Stoll.  High risk breast cancer in young women. , 1991, European journal of cancer.

[30]  L. Schover,et al.  The impact of breast cancer on sexuality, body image, and intimate relationships , 1991, CA: a cancer journal for clinicians.

[31]  P. Fedor-Freybergh.  THE INFLUENCE OF OESTROGENS ON THE WELLBEING AND MENTAL PERFORMANCE IN CLIMACTERIC AND POSTMENOPAUSAL WOMEN , 1977, Acta obstetricia et gynecologica Scandinavica. Supplement.